Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.

Authors: Nomoto, Hiroshi, Furusawa, Sho, Yokoyama, Hiroki, Suzuki, Yuka, Izumihara, Rimi, Oe, Yuki, Takahashi, Kiyohiko, Miya, Aika, Kameda, Hiraku, Cho, Kyu Yong, Takeuchi, Jun, Kurihara, Yoshio, Nakamura, Akinobu, Atsumi, Tatsuya

Source: Journal of Clinical Endocrinology & Metabolism; Mar2025, Vol. 110 Issue 3, pe583-e591, 9p

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.

Authors: Kitsunai, Hiroya, Shinozaki, Yuka, Furusawa, Sho, Kitao, Naoyuki, Ito, Miki, Kurihara, Hiroyoshi, Oba-Yamamoto, Chiho, Takeuchi, Jun, Nakamura, Akinobu, Takiyama, Yumi, Nomoto, Hiroshi

Source: Pharmaceuticals (14248247); Jan2025, Vol. 18 Issue 1, p129, 14p

Subject Terms: GLUCAGON-like peptide-1 receptor, HEPATIC fibrosis, TYPE 2 diabetes, WILCOXON signed-rank test, GLUCAGON-like peptide-1 agonists, ALANINE aminotransferase

Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria

Authors: Takahashi, Kiyohiko, Nakamura, Akinobu, Furusawa, Sho, Yokozeki, Kei, Sugawara, Hajime, Yanagisawa, Hideyuki, Akikawa, Kazumasa, Kikuchi, Hideaki

Source: In Journal of Clinical & Translational Endocrinology December 2020 22

Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study (SWITCH‐SEMA 2 study)

Authors: Furusawa, Sho¹ (AUTHOR), Nomoto, Hiroshi¹ (AUTHOR) hnomoto@med.hokudai.ac.jp, Yokoyama, Hiroki² (AUTHOR), Suzuki, Yuka¹ (AUTHOR), Tsuzuki, Atsushi¹ (AUTHOR), Takahashi, Kiyohiko³ (AUTHOR), Miya, Aika¹ (AUTHOR), Kameda, Hiraku¹ (AUTHOR), Cho, Kyu Yong¹ (AUTHOR), Takeuchi, Jun⁴ (AUTHOR), Nagai, So⁵ (AUTHOR), Taneda, Shinji⁶ (AUTHOR), Kurihara, Yoshio⁷ (AUTHOR), Nakamura, Akinobu¹ (AUTHOR), Atsumi, Tatsuya¹ (AUTHOR)

Source: Diabetes, Obesity & Metabolism. Mar2024, Vol. 26 Issue 3, p961-970. 10p.

Subject Terms: *GLYCEMIC control, *CD26 antigen, *TYPE 2 diabetes, *SODIUM-glucose cotransporters, *SEMAGLUTIDE, *INSULIN aspart, *MULTIPLE regression analysis

Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase‐4 inhibitor plus low‐dose metformin: A multicenter, prospective, randomized, open‐label, parallel‐group comparison study (MEGMI study)

Authors: Takahashi, Akihiro¹ (AUTHOR), Nomoto, Hiroshi^1,2 (AUTHOR) hnomoto@asahikawa-med.ac.jp, Yokoyama, Hiroki³ (AUTHOR), Yokozeki, Kei¹ (AUTHOR), Furusawa, Sho¹ (AUTHOR), Oe, Yuki¹ (AUTHOR), Kameda, Reina¹ (AUTHOR), Kawata, Shinichiro⁴ (AUTHOR), Miyoshi, Arina⁵ (AUTHOR), Nagai, So⁶ (AUTHOR), Miya, Aika¹ (AUTHOR), Kameda, Hiraku¹ (AUTHOR), Nakamura, Akinobu¹ (AUTHOR), Atsumi, Tatsuya¹ (AUTHOR)

Source: Diabetes, Obesity & Metabolism. Dec2024, p1. 11p. 2 Illustrations.

Subject Terms: *FATTY liver, *GLYCEMIC control, *TYPE 2 diabetes, *LIVER enzymes, *GLYCOSYLATED hemoglobin, *CD26 antigen, *SODIUM-glucose cotransporters